Skip to main content

Table 4 Association of cumulative TyG index with CVD-sensitivity analysis

From: Cumulative triglyceride-glucose index is a risk for CVD: a prospective cohort study

 

Analysis 1

Analysis 2

Analysis 3

Analysis 4

 

CVD

MI

Stoke

CVD

MI

Stoke

CVD

MI

Stoke

CVD

MI

Stoke

Quartiles

Q1

Ref

Ref

Ref

Ref

Ref

Ref

Ref

Ref

Ref

Ref

Ref

Ref

Q2

1.26 (1.07–1.49)

1.49 (0.99–2.23)

1.23 (1.02–1.47)

1.29 (1.11–1.50)

1.53 (1.07–2.19)

1.22 (1.03–1.43)

1.30 (1.12–1.52)

1.35 (0.95–1.92)

1.24 (1.05–1.47)

1.20 (1.04–1.40)

1.38 (0.98–1.96)

1.16 (0.99–1.36)

Q3

1.20 (1.02–1.42)

1.19 (0.79–1.80)

1.21 (1.01–1.44)

1.27 (1.09–1.47)

1.31 (0.91–1.88)

1.21 (1.03–1.42)

1.27 (1.09–1.48)

1.07 (0.74–1.54)

1.23 (1.04–1.45)

1.14 (0.99–1.33)

1.12 (0.78–1.60)

1.14 (0.94–1.34)

Q4

1.35 (1.15–1.59)

1.34 (0.89–2.02)

1.36 (1.14–1.63)

1.43 (1.23–1.66)

1.60 (1.11–2.29)

1.33 (1.13–1.57)

1.52 (1.31–1.77)

1.34 (0.94–1.91)

1.40 (1.19–1.66)

1.25 (1.06–1.46)

1.24 (0.85–1.80)

1.24 (1.04–1.47)

Time exposure duration

0 year

Ref

Ref

Ref

Ref

Ref

Ref

Ref

Ref

Ref

2 years

1.28 (1.12–1.47)

1.46 (1.04–2.04)

1.26 (1.09–1.45)

1.22 (1.07–1.38)

1.51 (1.13–2.01)

1.16 (1.01–1.33)

1.24 (1.09–1.41)

1.51 (1.13–2.02)

1.20 (1.05–1.38)

4 years

1.26 (1.08–1.48)

1.22 (0.81–1.85)

1.27 (1.06–1.51)

1.23 (1.06–1.43)

1.24 (0.86–1.79)

1.23 (1.01–1.45)

1.19 (1.02–1.39)

1.21 (0.84–1.74)

1.19 (1.01–1.40)

6 years

1.24 (1.04–1.48)

1.54 (1.01–2.34)

1.18 (0.96–1.43)

1.10 (0.92–1.31)

1.32 (0.88–1.97)

1.05 (0.86–1.28)

1.18 (0.99–1.39)

1.26 (0.85–1.87)

1.15 (0.95–1.38)

8 years

1.51 (1.26–1.79)

2.08 (1.39–3.10)

1.42 (1.17–1.72)

1.42 (1.20–1.69)

2.11 (1.46–3.03)

1.29 (1.06–1.57)

1.46 (1.24–1.71)

1.78 (1.23–2.57)

1.37 (1.15–1.65)

  1. Multivariable model adjusted for sex, income, educational level, drinking, smoking, diabetes, hypertension, lipid‐lowering medication, BMI, RHR, HDL-C, LDL-C, UA, Hs-CRP
  2. Analysis1 excluded participants events occurring in the first 2 years of follow-up (n = 884); Analysis2 excluded participants with diabetes at baseline (n = 3320); Analysis3 excluded received treatment with lipid lowering medication at baseline and follow-up (n = 5866); Analysis4 additional adjustment for TyG index at baseline